Jose R Conejo-Garcia

Associate Professor; Program Leader
Tumor Microenvironment and Metastasis
The Wistar Institute
E-mail: jrconejo@wistar.org
Page: http://www.wistar.org/lab/jose-r-conejo-garcia-md-phd

Fields of interest: 

Tumor immunology, immunotherapy, tumor microenvronment, miRNA biology

 

Recent publications:

Cubillos-Ruiz JR, Baird J, Rutkowski M, Scarlett UK,  Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood N, Korc M, Fiering S, Sempere L, Conejo-Garcia JR:
Reprogramming tumor-associated dendritic cells in vivo using microRNA mimetics triggers protective immunity against ovarian cancer.
Cancer Res.,In Press. doi:10.1158/0008-5472.CAN-11-3160 (2012)

Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez J, Weaver J, Fiering S, Conejo-Garcia JR:
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.
J. Exp. Med.,209: 495-506 (2012)

Cubillos-Ruiz J.R., Martinez D., Scarlett U.K., Rutkowski M.R., Nesbeth Y.C., Camposeco-Jacobs A.L., Conejo-Garcia J.R.:
CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.
Oncotarget,1: 329-338 (2010)

Nesbeth Y, Martinez D, Toraya S, Scarlett U,  Cubillos-Ruiz J,  Rutkowski M, Conejo-Garcia J.:
CD4+ T cells elicit host immune responses to MHC-II- ovarian cancer through CD40-mediated licensing of dendritic cells and CCL5 secretion.
J. Immunol.,184: 5654-62 (2010)

Robinson R.T., Khader S.A., Martino C.A., Fountain J.J., Teixeira-Coelho M., Pearl J.E., Smiley S.T., Winslow G.M., Woodland D., Walter M.J., Conejo-Garcia J.R., Gubler U. & Cooper A.M:
Mycobacterium tuberculosis infection induces IL12R1 splicing 1 to generate a novel IL12Rβ1 isoform that enhances DC migration.
J. Exp. Med.,207:591-605 (2010)

Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Ahonen CL,Conejo-Garcia JR.:
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.
Cancer Res., 69: 7329–37 (2009)

Cubillos-Ruiz J., Engle X., Scarlett U., Martinez D., Barber A., Elgueta R., Wang L., Nesbeth Y., Durant Y., Gewirtz A.T., Sentman C.L., Kedl R., Conejo-Garcia JR:
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.
J. Clin. Invest., 119: 2231-44 (2009)

Nesbeth Y, Scarlett U, Cubillos-Ruiz J, Martinez D,  Engle X, Turk, MJ, Conejo-Garcia JR:
Elimination of ovarian cancer dendritic cells boosts endogenous anti-tumor immunity elicited by adoptively transferred lymphocytes.
Cancer Res.;69: 6331-6338 (2009)

Huarte E, Cubillos-Ruiz J, Nesbeth Y, Scarlett U, Martinez D, Buckanovich RJ, Benencia F, Stan R, Keler T, Sarobe P, Sentman CL,Conejo-Garcia JR:
Depletion of dendritic cells delays ovarian cancer progression by boosting anti-tumor immunity.
Cancer Res., 68: 7684-91 (2008)

 Huarte E, Cubillos-Ruiz J, Nesbeth Y, Scarlett U, Martinez D, Pioli P, Rigby W, Guyre P, Conejo-Garcia, JR.:
PILAR is a novel modulator of human T cell expansion. 
Blood, 112: 1259-68 (2008)